Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade) [Seeking Alpha]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Seeking Alpha
Yutrepia's Q4 sales reached $90.1M, with 75% of starts from prostacycline-naive patients, yet market share gains may be capped by shifting patient preferences. Major competitive risks loom post-2027 from United Therapeutics' TreSMI and ralinepag, as well as Insmed's once-daily TPIP, challenging LQDA's growth trajectory. L606, Liquidia's twice-daily DPI, offers only incremental convenience and faces less favorable economics due to royalty obligations, limiting its strategic response. Klaus Vedfelt/DigitalVision via Getty Images Overview Liquidia's stock ( LQDA ) is up a solid 16% since my " Sell " rating to begin the year. Its commercialization of Yutrepia (treprostinil powder) has gone quite well. My last analysis followed Yutrepia's first full quarter This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win [Seeking Alpha]Seeking Alpha
- United Therapeutics (UTHR) had its price target raised by HC Wainwright from $600.00 to $660.00. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics (UTHR) had its price target raised by Wells Fargo & Company from $486.00 to $575.00. They now have an "equal weight" rating on the stock.MarketBeat
- United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo [Yahoo! Finance]Yahoo! Finance
- United Therapeutics (UTHR) had its price target raised by Bank of America Corporation from $569.00 to $626.00. They now have a "neutral" rating on the stock.MarketBeat
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- UTHR's page on the SEC website